Compare ACNT & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACNT | OVID |
|---|---|---|
| Founded | 1945 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.8M | 117.3M |
| IPO Year | N/A | 2017 |
| Metric | ACNT | OVID |
|---|---|---|
| Price | $15.21 | $1.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.60 |
| AVG Volume (30 Days) | 84.6K | ★ 1.7M |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $171,413,000.00 | $6,610,000.00 |
| Revenue This Year | $22.72 | $1,077.56 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $161.57 | ★ N/A |
| Revenue Growth | 65.05 | ★ 945.89 |
| 52 Week Low | $10.76 | $0.24 |
| 52 Week High | $15.69 | $2.01 |
| Indicator | ACNT | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 68.35 | 55.94 |
| Support Level | $14.74 | $1.45 |
| Resistance Level | $15.69 | $1.75 |
| Average True Range (ATR) | 0.59 | 0.14 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 76.54 | 67.22 |
Ascent Industries Co is a specialty chemicals platform focused on the development, production, and distribution of tailored, performance-driven chemical solutions. It has one reportable segment: Specialty Chemicals. The Specialty Chemicals segment includes the operating results of the Company's plants involved in the production of specialty chemicals and produces critical ingredients and process aids for the oil & gas, household, industrial and institutional (HII), personal care, coatings, adhesives, sealants and elastomers (CASE), pulp and paper, textile, automotive, agricultural, water treatment, construction and other industries.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.